• Total Portfolio Value: $1.5B (23 stocks)
• New Position: $ADRX ($134M)
• Biggest Add: $ALKS (+63% shares)
• Sold Out: $DNTH
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#13F #Investing
• Total Portfolio Value: $1.5B (23 stocks)
• New Position: $ADRX ($134M)
• Biggest Add: $ALKS (+63% shares)
• Sold Out: $DNTH
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#13F #Investing
Ticker: $DNTH
Company: Dianthus Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 92
Recent Close: $92.48
52-Week High: $117.88
52-Week High Date: 08-19-2026
% Off 52-Week High: -21.55%
52-Week Low: $34.29
Ticker: $DNTH
Company: Dianthus Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 92
Recent Close: $92.48
52-Week High: $117.88
52-Week High Date: 08-19-2026
% Off 52-Week High: -21.55%
52-Week Low: $34.29
Hub: https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=dnth
Not investment advice.
Hub: https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=dnth
Not investment advice.
RYAN SAVITZ, a Officer, filed a notice of intent to sell 124,042 shares of common stock, valued at approximately $10,671,333.26, on 11/09/2026.
RYAN SAVITZ, a Officer, filed a notice of intent to sell 124,042 shares of common stock, valued at approximately $10,671,333.26, on 11/09/2026.
#$DNTH FAQ + PDF report: www.merlintrader.com/dianthus-the...
#$DNTH FAQ + PDF report: www.merlintrader.com/dianthus-the...
https://fundspec.ai/s/DNTH/earnings
Pick a trader profile and get signals tuned to how you actually trade.
https://fundspec.ai/s/DNTH/earnings
Pick a trader profile and get signals tuned to how you actually trade.
On November 4, 2026, Dianthus Therapeutics, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
On November 4, 2026, Dianthus Therapeutics, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-dm77cfa6et2q.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-dm77cfa6et2q.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-c224g66l9ytw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-c224g66l9ytw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-to-participate-in-five-investor-conferences-ffpuomqt0keg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-to-participate-in-five-investor-conferences-ffpuomqt0keg.html?utm_source=stocktitan-bluesky&utm_medium=social
• Holder: Vanguard Capital Management
• Stake: 0 → 5.08% (about $235M)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: Vanguard Capital Management
• Stake: 0 → 5.08% (about $235M)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
Information only — not investment advice.
https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/
Information only — not investment advice.
https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/
https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/
https://www.merlintrader.com/dianthus-therapeutics-dnth-stock-hub/
CARR EDWARD (CHIEF ACCOUNTING OFFICER) sold 20,000 shares at an average price of $101.3823 per common share. (Date: 2026-09-17)
CARR EDWARD (CHIEF ACCOUNTING OFFICER) sold 20,000 shares at an average price of $101.3823 per common share. (Date: 2026-09-17)
$DNTH 8-K → https://filingdiff.com/ticker/DNTH/0001193125-26-103053/
$DNTH 8-K → https://filingdiff.com/ticker/DNTH/0001193125-26-103053/
somehow reminds me of the work of GE (Tony) Fogg depicted in this post fro a few years ago bsky.app/profile/dnth...
“There is nothing, Sir, too little for so little a creature as man. It is by studying the little things that we attain the great art as having as little misery and as much happiness as possible" Samuel Johnson
Snow microbes by GE (Tony) Fogg
somehow reminds me of the work of GE (Tony) Fogg depicted in this post fro a few years ago bsky.app/profile/dnth...
bsky.app/profile/dnth...
This replaces my earlier erroneous re-post that recklessly got the units wrong. This important message does not need folks (who should know better) making stupid mistakes about the units - my apologies
bsky.app/profile/dnth...
bsky.app/profile/dnth...
……..phew
bsky.app/profile/dnth...
Raining, 1 oC and gravel paths turned to mud sponges - 😀
#WinterCycling is starting